CONFIRMEDDate confidence: CONFIRMEDStated as firmHow firmly the source words the date: confirmed, scheduled, estimated, delayed or unverified.Show all CONFIRMED pins87% CONFIDENCEOverall confidence: 87%How well the pin's source and references back up its dates.Weighted average of how firmly 4 references, the source included, support the pin's start and end times; a reference counts half as much for every 180 days older than the newestShow all pins at 75% confidence or better
Amgen's[1][4] 10-Q for the quarter to 30 June 2026 states 'On April 27, 2026, CDER issued a proposal to withdraw approval of TAVNEOS'; Amgen's Tavneos update page confirms the proposal.On 27 April 2026 the FDA's drug centre issued a proposal to withdraw approval of Amgen's Tavneos for ANCA-associated vasculitis, alleging lack of substantial evidence of effectiveness; Amgen disagrees and the drug stays on the market.